Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
1.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.8K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expansion and safety profile of CD28-costimulated anti-CD19 CAR T cells in B-cell lymphoma versus autoimmune disease.

HemaSphere·2026
Same author

A novel multiplex approach for the comprehensive analysis of the Epstein-Barr virus-specific humoral immune response.

Frontiers in cellular and infection microbiology·2026
Same author

CMV reactivation post allogeneic stem cell transplantation decreases relapse risk and survival, and increases NRM - a single center analysis.

Leukemia & lymphoma·2026
Same author

The composition of MDSC-subpopulations PMN-like, M-like, and e-like MDSC is associated with the severity of infectious mononucleosis in pediatric patients.

Frontiers in immunology·2026
Same author

CD19 CAR-T therapy induces remission in refractory autoimmune hemolytic anemia with ITP and antiphospholipid syndrome.

Med (New York, N.Y.)·2026
Same author

Author Correction: 7-Dehydrocholesterol is an endogenous suppressor of ferroptosis.

Nature·2026

Related Experiment Video

Updated: May 6, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

7.7K

Targeting c-MYC with T-cells.

Florian Helm1, Thomas Kammertoens, Frank M Lehmann

  • 1Department of Immunology, Charité Berlin, Berlin, Germany.

Plos One
|October 17, 2013
PubMed
Summary

Targeting the proto-oncogene c-MYC with T-cells shows promise for cancer therapy. Immunization with human c-MYC protein generated T-cells that protected mice against lymphoma.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.2K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K

Related Experiment Videos

Last Updated: May 6, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

7.7K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.2K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The proto-oncogene c-MYC is over-expressed in many cancers, including Burkitt's lymphoma, making it a critical therapeutic target.
  • Tumor cells often depend on c-MYC for growth, creating an
  • addiction
  • that can be exploited for anti-cancer strategies.

Purpose of the Study:

  • To investigate the potential of targeting human c-MYC using a xenogenic vaccination strategy in a mouse model.
  • To identify immunogenic epitopes within human c-MYC that can elicit a protective anti-tumor immune response.

Main Methods:

  • Xenogenic vaccination of C57BL/6 mice using human c-MYC protein or peptides.
  • Identification of MHC class II-restricted CD4+ and MHC class I-restricted CD8+ T-cell epitopes.
  • Assessment of protection against a lethal lymphoma challenge after prime/boost immunization.

Main Results:

  • Human c-MYC protein contains immunogenic epitopes presented in the context of the murine H2(b) haplotype.
  • A specific MHC class I-restricted CD8+ T-cell epitope (SSPQGSPEPL) was identified.
  • Prime/boost immunization protected up to 25% of mice from lymphoma, with protection mediated by cytotoxic CD8+ T-cells.

Conclusions:

  • Oncogenic c-MYC can be targeted effectively using specific T-cells generated through vaccination.
  • The identified c-MYC epitope (SSPQGSPEPL) is a potential target for developing novel immunotherapies against c-MYC-driven cancers.